A groundbreaking two-stage diagnostic model distinguishes between clinical and pre-clinical obesity, preventing millions of misdiagnoses and paving the way for truly personalized healthcare
Researchers have found that with increasing popularity of GLP-1 drugs, their consumption has significantly increased among those with no FDA approved indications
The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide
Roswell Park reveals that exercise was linked to fewer immune-suppressing cells and greater tumor-fighting activity in preclinical and patient samples.